Q1 Earnings Estimate for OptimizeRx Issued By Roth Capital

OptimizeRx Co. (NASDAQ:OPRX - Free Report) - Equities researchers at Roth Capital issued their Q1 2026 EPS estimates for OptimizeRx in a research note issued on Wednesday, March 12th. Roth Capital analyst R. Baldry forecasts that the company will earn ($0.19) per share for the quarter. The consensus estimate for OptimizeRx's current full-year earnings is ($0.33) per share. Roth Capital also issued estimates for OptimizeRx's Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.05) EPS and Q4 2026 earnings at $0.44 EPS.

Several other research analysts have also recently weighed in on OPRX. Stephens began coverage on shares of OptimizeRx in a report on Friday, December 20th. They set an "equal weight" rating and a $5.50 price objective for the company. Lake Street Capital reissued a "buy" rating and set a $11.00 price objective on shares of OptimizeRx in a report on Tuesday, December 24th. Royal Bank of Canada reissued a "sector perform" rating and set a $6.00 price objective (down from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th. B. Riley raised shares of OptimizeRx to a "strong-buy" rating in a report on Wednesday, March 12th. Finally, JMP Securities reissued a "market outperform" rating and set a $8.00 price objective on shares of OptimizeRx in a report on Thursday, February 6th. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, OptimizeRx has a consensus rating of "Moderate Buy" and a consensus price target of $9.06.

Remove Ads

OptimizeRx Stock Up 0.9 %

Shares of NASDAQ OPRX traded up $0.08 during midday trading on Monday, hitting $8.69. The stock had a trading volume of 769,705 shares, compared to its average volume of 255,459. The business's 50 day moving average is $5.71 and its 200-day moving average is $5.92. The company has a market cap of $160.08 million, a P/E ratio of -6.59 and a beta of 1.31. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $14.13. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29.

Insiders Place Their Bets

In other news, Director James Paul Lang purchased 321,408 shares of the company's stock in a transaction on Friday, March 14th. The stock was acquired at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the transaction, the director now directly owns 389,452 shares in the company, valued at $2,959,835.20. This trade represents a 472.35 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 6.10% of the company's stock.

Hedge Funds Weigh In On OptimizeRx

Hedge funds have recently modified their holdings of the company. Barclays PLC boosted its position in shares of OptimizeRx by 358.5% in the third quarter. Barclays PLC now owns 26,934 shares of the company's stock worth $208,000 after purchasing an additional 21,060 shares during the period. Janney Montgomery Scott LLC bought a new position in shares of OptimizeRx in the third quarter worth approximately $810,000. BNP Paribas Financial Markets boosted its position in shares of OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company's stock worth $28,000 after acquiring an additional 2,414 shares during the last quarter. Quest Partners LLC boosted its position in shares of OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company's stock worth $76,000 after acquiring an additional 9,739 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of OptimizeRx during the fourth quarter worth $51,000. 76.47% of the stock is currently owned by institutional investors.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.